Cargando…

Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer

PURPOSE: Breast cancer (BC) is one of the most common malignancies globally, and millions of women worldwide are diagnosed with BC every year. Up to 70% of BC patients are estrogen receptor (ER)-positive. Numerous studies have shown that tamoxifen has a significant therapeutic effect on both primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Dehai, Shi, Libo, Bu, Yuhui, Li, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597414/
https://www.ncbi.nlm.nih.gov/pubmed/31281726
http://dx.doi.org/10.4048/jbc.2019.22.e29
_version_ 1783430578555584512
author Yu, Dehai
Shi, Libo
Bu, Yuhui
Li, Weidong
author_facet Yu, Dehai
Shi, Libo
Bu, Yuhui
Li, Weidong
author_sort Yu, Dehai
collection PubMed
description PURPOSE: Breast cancer (BC) is one of the most common malignancies globally, and millions of women worldwide are diagnosed with BC every year. Up to 70% of BC patients are estrogen receptor (ER)-positive. Numerous studies have shown that tamoxifen has a significant therapeutic effect on both primary and metastatic ER-positive BC patients. Although tamoxifen is currently one of the most successful therapeutic agents for BC, a significant proportion of patients will eventually become resistant to tamoxifen, leading to tumor recurrence and metastasis. Knowledge about the development of tamoxifen resistance in BC patients is still limited. METHODS: We applied a loss-and-gain method to study the biological functional role of cell division cycle associated 8 (CDCA8) in tamoxifen resistance in BC cells. RESULTS: We found that CDCA8 was significantly elevated in tamoxifen-resistant BC cells. Knockdown of CDCA8 expression significantly inhibited the proliferation of tamoxifen-resistant BC cells and reduced their resistance to tamoxifen. In contrast, overexpression of CDCA8 promoted the growth of tamoxifen-sensitive BC cells and induced their resistance to tamoxifen. CONCLUSION: In this study, we reported that CDCA8 is a key regulator of tamoxifen resistance in BC, suggesting that CDCA8 may serve as a potential therapeutic target for BC treatment.
format Online
Article
Text
id pubmed-6597414
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Breast Cancer Society
record_format MEDLINE/PubMed
spelling pubmed-65974142019-07-05 Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer Yu, Dehai Shi, Libo Bu, Yuhui Li, Weidong J Breast Cancer Original Article PURPOSE: Breast cancer (BC) is one of the most common malignancies globally, and millions of women worldwide are diagnosed with BC every year. Up to 70% of BC patients are estrogen receptor (ER)-positive. Numerous studies have shown that tamoxifen has a significant therapeutic effect on both primary and metastatic ER-positive BC patients. Although tamoxifen is currently one of the most successful therapeutic agents for BC, a significant proportion of patients will eventually become resistant to tamoxifen, leading to tumor recurrence and metastasis. Knowledge about the development of tamoxifen resistance in BC patients is still limited. METHODS: We applied a loss-and-gain method to study the biological functional role of cell division cycle associated 8 (CDCA8) in tamoxifen resistance in BC cells. RESULTS: We found that CDCA8 was significantly elevated in tamoxifen-resistant BC cells. Knockdown of CDCA8 expression significantly inhibited the proliferation of tamoxifen-resistant BC cells and reduced their resistance to tamoxifen. In contrast, overexpression of CDCA8 promoted the growth of tamoxifen-sensitive BC cells and induced their resistance to tamoxifen. CONCLUSION: In this study, we reported that CDCA8 is a key regulator of tamoxifen resistance in BC, suggesting that CDCA8 may serve as a potential therapeutic target for BC treatment. Korean Breast Cancer Society 2019-06-07 /pmc/articles/PMC6597414/ /pubmed/31281726 http://dx.doi.org/10.4048/jbc.2019.22.e29 Text en © 2019 Korean Breast Cancer Society https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Yu, Dehai
Shi, Libo
Bu, Yuhui
Li, Weidong
Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer
title Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer
title_full Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer
title_fullStr Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer
title_full_unstemmed Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer
title_short Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer
title_sort cell division cycle associated 8 is a key regulator of tamoxifen resistance in breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597414/
https://www.ncbi.nlm.nih.gov/pubmed/31281726
http://dx.doi.org/10.4048/jbc.2019.22.e29
work_keys_str_mv AT yudehai celldivisioncycleassociated8isakeyregulatoroftamoxifenresistanceinbreastcancer
AT shilibo celldivisioncycleassociated8isakeyregulatoroftamoxifenresistanceinbreastcancer
AT buyuhui celldivisioncycleassociated8isakeyregulatoroftamoxifenresistanceinbreastcancer
AT liweidong celldivisioncycleassociated8isakeyregulatoroftamoxifenresistanceinbreastcancer